JP2011513483A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513483A5
JP2011513483A5 JP2010550685A JP2010550685A JP2011513483A5 JP 2011513483 A5 JP2011513483 A5 JP 2011513483A5 JP 2010550685 A JP2010550685 A JP 2010550685A JP 2010550685 A JP2010550685 A JP 2010550685A JP 2011513483 A5 JP2011513483 A5 JP 2011513483A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
gsk
disease
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010550685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513483A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/001534 external-priority patent/WO2009145814A2/en
Publication of JP2011513483A publication Critical patent/JP2011513483A/ja
Publication of JP2011513483A5 publication Critical patent/JP2011513483A5/ja
Pending legal-status Critical Current

Links

JP2010550685A 2008-03-10 2009-03-10 タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン Pending JP2011513483A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3529008P 2008-03-10 2008-03-10
PCT/US2009/001534 WO2009145814A2 (en) 2008-03-10 2009-03-10 Pyrimidines and pyridines useful as inhibitors of protein kinases

Publications (2)

Publication Number Publication Date
JP2011513483A JP2011513483A (ja) 2011-04-28
JP2011513483A5 true JP2011513483A5 (enExample) 2012-09-06

Family

ID=41268452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550685A Pending JP2011513483A (ja) 2008-03-10 2009-03-10 タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン

Country Status (4)

Country Link
US (1) US20110224197A1 (enExample)
EP (1) EP2262498A2 (enExample)
JP (1) JP2011513483A (enExample)
WO (1) WO2009145814A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201412738A (zh) 2006-01-17 2014-04-01 Vertex Pharma 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
NZ577798A (en) 2006-12-21 2012-04-27 Vertex Pharma 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
DK2442809T3 (en) 2009-06-17 2016-12-19 Vertex Pharma Inhibitors of the replication of influenza virus
NZ601635A (en) 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CA2804471A1 (en) * 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused 4 -aminopyrimidines and use thereof as stimulators of soluble guanylate cyclases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
KR20120063283A (ko) * 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
PH12014500460A1 (en) 2011-09-02 2014-04-14 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
UA120278C2 (uk) 2011-11-25 2019-11-11 Адверіо Фарма Гмбх Заміщені 5-фтор-1н-піразолопіридини в кристалічній формі
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
ES2644781T3 (es) 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabiciclos sustituidos y su uso
BR112014027117B1 (pt) * 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
WO2013164321A1 (en) * 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators
CN103896856B (zh) * 2012-12-25 2016-06-08 叶龙 一种多取代单环嘧啶类jnk激酶抑制剂及其制备方法和用途
AP2015008670A0 (en) 2013-02-21 2015-08-31 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
WO2015004105A1 (de) 2013-07-10 2015-01-15 Bayer Pharma Aktiengesellschaft Benzyl-1h-pyrazolo[3,4-b]pyridine und ihre verwendung
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP2018525345A (ja) 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
CN108003092B (zh) * 2017-12-21 2021-04-02 重庆中邦科技有限公司 一种2,3-二氯吡啶的合成方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US20030153560A1 (en) * 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
ES2266258T3 (es) * 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
DE60232510D1 (de) * 2001-06-15 2009-07-16 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
US20040236110A1 (en) * 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
MXPA04010545A (es) * 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida.
ES2273043T3 (es) * 2002-08-02 2007-05-01 Vertex Pharmaceuticals Incorporated Composiciones de pirazol utiles como inhibidores de gsk-3.
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
JP2007526894A (ja) * 2003-07-16 2007-09-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲンシンターゼキナーゼ３インヒビターとしてのトリアゾロピリミジン誘導体
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US7507826B2 (en) * 2004-03-30 2009-03-24 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
ZA200704888B (en) * 2004-11-22 2009-02-25 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
AU2005316540A1 (en) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
KR20080016659A (ko) * 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
EP1749523A1 (en) * 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
TW201412738A (zh) * 2006-01-17 2014-04-01 Vertex Pharma 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
CA2641254A1 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
CA2648250A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
NZ577798A (en) * 2006-12-21 2012-04-27 Vertex Pharma 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
ATE526328T1 (de) * 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008112646A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
WO2008112642A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
AR067762A1 (es) * 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
US8173635B2 (en) * 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу

Similar Documents

Publication Publication Date Title
US20220241299A1 (en) Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
US8658668B2 (en) PI3 kinase/mTOR dual inhibitor
US11291666B2 (en) Uses
CA3077499C (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
UA75325C2 (en) Antiparasitic derivatives of artemisin (endoperoxides)
JP6893917B2 (ja) 神経変性疾患の処置
RU2009137390A (ru) Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ
CN104822392B (zh) 抑制活化的t‑细胞中il‑22表达的方法
Lee et al. Antiosteoporosis effects of a marine antimicrobial peptide pardaxin via regulation of the osteogenesis pathway
AU2024334590A1 (en) Stat6 degraders and uses thereof
Li et al. Behavioral alterations associated with a down regulation of HCN1 mRNA in hippocampal cornus ammon 1 region and neocortex after chronic incomplete global cerebral ischemia in rats
Feng et al. Stromal cell-derived factor 1 protects human periodontal ligament stem cells against hydrogen peroxide-induced apoptosis
JP2019526584A (ja) 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞
Tzeng et al. Neuronal morphological change of size-sieved stem cells induced by neurotrophic stimuli
Arscott et al. Interferon β-1b directly modulates human neural stem/progenitor cell fate
WO2021169984A1 (zh) 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
EP1619244B1 (en) Use of stem cells for inducing neural differentiation
JP2026506930A (ja) パーキンソン病、並びに他の一次性及び二次性パーキンソニアン障害を処置するための組合せ
Joshi et al. Identification of small molecule activators for ErbB 4 receptor to enhance oligodendrocyte regeneration by in silico approach
JP2020532576A (ja) 神経変性疾患の処置
Nguyen et al. Rat oligodendroglial cell lines express a functional receptor for the chemokine CCL3 (macrophage inflammatory protein-1alpha)
Marhalim et al. Synergistic effects of GSK3 and p38 MAPK inhibitors on growth of Plasmodium falciparum ex vivo.
US11786507B2 (en) Methods of treating HIV-associated neurological disorders (HAND)
US20250177422A1 (en) Co-administration of a co-crystal of psilocybin and psilocin with an atypical antipsychotic
ITMI20131218A1 (it) Nuovi ureido derivati di acidi naftalensolfonici